Beijing Gene+ Technology, also known as Beijing Gene Plus, is a prominent player in the health care and life sciences industries. The company, founded in 2015, has a compelling slogan: "Empowering Cancer Prevention and Early Detection with Advanced Gene Testing Services." The core focus of Beijing Gene+ is to offer gene testing services targeted at cancer prevention and early detection, delivering vital data to bolster the implementation of precision medicine.
Operating in approximately 100 hospitals, Beijing Gene+ has made significant strides in serving thousands of cancer patients across China. The company finalized a noteworthy CNY750.00M Series C investment on 22 July 2021, attracting backing from a roster of esteemed investors including GGV Capital, CCB International, Harvest Capital Management, Baidu Venture, Fortune Capital, CCB Capital, and Alibaba Health Information Technology.
